<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/7BE584D4-9F36-4F21-9CA7-63766CD614C6"><gtr:id>7BE584D4-9F36-4F21-9CA7-63766CD614C6</gtr:id><gtr:name>MRC Centre Oxfordshire</gtr:name><gtr:department>Human Immunology Unit</gtr:department><gtr:address><gtr:line1>Harwell</gtr:line1><gtr:postCode>OX11 0RD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BE584D4-9F36-4F21-9CA7-63766CD614C6"><gtr:id>7BE584D4-9F36-4F21-9CA7-63766CD614C6</gtr:id><gtr:name>MRC Centre Oxfordshire</gtr:name><gtr:address><gtr:line1>Harwell</gtr:line1><gtr:postCode>OX11 0RD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C7C874D5-8DF0-48ED-89AF-82171CCD4CCD"><gtr:id>C7C874D5-8DF0-48ED-89AF-82171CCD4CCD</gtr:id><gtr:firstName>Ana</gtr:firstName><gtr:otherNames>Paula</gtr:otherNames><gtr:surname>Guimar?es-Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500430"><gtr:id>D4FCE4EA-DA26-4B9A-A2E9-825BE60A6AF3</gtr:id><gtr:title>Investigation of the immunological correlates of viraemic control in HIV-infected subjects undergoing therapeutic immu</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500430</gtr:grantReference><gtr:abstractText>The only effective treatment for infection with the human immunodeficiency virus (HIV), the cause of AIDS, is a combination of three anti-HIV drugs taken for the rest of the infected person?s lifetime. Of the 40 million people infected worldwide, the vast majority have no access to these drugs. We are exploring alternative ways of keeping HIV in check without continuous drug treatment. Using a vaccine to boost the body?s immune defences against the virus is one possible strategy. We are currently testing vaccines in HIV-positive people who are already stabilised on anti-HIV drugs as this should give the vaccines the best chance to work. However, it is necessary to stop the patient?s treatment temporarily, while carefully monitoring the amount of virus in his / her bloodstream, in order to assess whether the vaccine has had a beneficial effect. If this approach shows promise in initial trials, we would aim to improve it so that it can be used on a large scale, as this could ultimately be significantly less costly and harmful than long-term drug treatment, and therefore a realistic possibility for people in urgent need.</gtr:abstractText><gtr:technicalSummary>Aims
To assess the effect in chronic HIV-1 infected subjects of therapeutic immunisation with a Clade A HIV-1 / recombinant Modified Vaccinia Virus Ankara vaccine (MVA.HIVA) on viral load during antiretroviral treatment interruption.
To investigate possible immunological correlates of HIV-1 viraemia control.
Relevance
Lifelong treatment with combination antiretroviral therapy (HAART) is currently the only means to prevent progression of HIV-1 disease yet the vast majority of HIV-1 infected individuals have no access to HAART. Long-term therapy is associated with the risk of serious adverse effects and the emergence of drug-resistant viruses. Alternative therapeutic strategies are urgently needed.
Scientific objectives
- To extent preliminary immunogenicity studies of MVA.HIVA by evaluating a larger cohort of chronically infected HAART-treated subjects.
- To evaluate the capacity of vaccine stimulated T cells to reduce plasma viral load after HAART interruption. 
- To identify the characteristics of T cell responses associated with virological control
Research plan &amp;amp; methodology
Asymptomatic HIV-1-infected individuals under full HAART suppression will be enrolled in a randomised, double-blinded, placebo-controlled trial of intradermal MVA.HIVA immunisation followed by a supervised HAART interruption. Quantitative and qualitative CD4+ and CD8+ T cell assays will be performed on samples of peripheral blood mononuclear cells (PBMC) obtained before and after immunisation. These include ELISPOT, tetramer, cytokine secretion and dye-based proliferation assays and assessment of activation and memory phenotype. The results will be correlated with HIV-1 plasma viral load (pVL) dynamics after HAART withdrawal. The kinetics and quality of T cell responses in relation to HIV-1 pVL decline and viral load set-point will be examined. These studies will involve a major collaboration with the HIV Clinical Trials Centre at St. Mary?s Hospital, London and with the MRC Clinil Trials Unit. This research is needed to obtain a ?proof-of concept? for therapeutic immunisation and to guide further vaccine development. The long-term goal is to improve HIV therapy and to make it affordable to all.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>204059</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G0500430</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>